Pre-treatment [¹⁸F]FDG PET/CT for assessing bone marrow involvement and prognosis in patients with newly diagnosed peripheral T-cell lymphoma.

IF 2 4区医学 Q3 HEMATOLOGY

Hematology Pub Date : 2024-12-01 Epub Date: 2024-03-11 DOI:10.1080/16078454.2024.2325317

Jing Chen, Yi Zhao

{"title":"Pre-treatment [18F]FDG PET/CT for assessing bone marrow involvement and prognosis in patients with newly diagnosed peripheral T-cell lymphoma.","authors":"Jing Chen, Yi Zhao","doi":"10.1080/16078454.2024.2325317","DOIUrl":null,"url":null,"abstract":"Purpose: To explore the value of [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in assessing bone marrow involvement (BMI) and prognosis in newly diagnosed peripheral T-cell lymphomas (PTCLs) before treatment.Methods: This retrospective study included 201 eligible PTCLs who received pre-bone marrow biopsy (BMB) and PET/CT. The status of bone marrow (BM) by PET was assessed using a visual examination and a quantitative index (the maximal standardized uptake value [SUVmax] of BM divided by the SUVmax of the liver [M/L]).Results: Totally 148 patients had no evidence of BMI by PET or BMB; BMI was detected by both methods in 16 patients. The sensitivity and specificity of PET/CT for patients with confirmed BMI by BMB were 43.2% and 90.2%, respectively (κ = 0.353). In addition, 25 patients assessed by PET/CT staging (having stage I to II disease) had no evidence of BMI detected by both PET/CT and BMB. Image-guided biopsy was also recommended when PET/CT showed a focal FDG uptake outside the iliac crest. Survival analysis revealed that BMB was significant for overall survival (OS) (P = 0.020) while M/L for both progression free survival (P = 0.002) and OS (P < 0.001). In multivariate analysis, M/L (HR 1.825, 95% CI 1.071-3.110, P = 0.027) was an independent prognostic factor for OS. There were no statistical differences at the genetic level about BMI confirmed by PET or BMB.Conclusion: PET/CT has a complementary role in assessing BMI and an ability to predict prognosis in PTCL patients.","PeriodicalId":13161,"journal":{"name":"Hematology","volume":"29 1","pages":"2325317"},"PeriodicalIF":2.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/16078454.2024.2325317","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To explore the value of [¹⁸F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in assessing bone marrow involvement (BMI) and prognosis in newly diagnosed peripheral T-cell lymphomas (PTCLs) before treatment.

Methods: This retrospective study included 201 eligible PTCLs who received pre-bone marrow biopsy (BMB) and PET/CT. The status of bone marrow (BM) by PET was assessed using a visual examination and a quantitative index (the maximal standardized uptake value [SUV_max] of BM divided by the SUV_max of the liver [M/L]).

Results: Totally 148 patients had no evidence of BMI by PET or BMB; BMI was detected by both methods in 16 patients. The sensitivity and specificity of PET/CT for patients with confirmed BMI by BMB were 43.2% and 90.2%, respectively (κ = 0.353). In addition, 25 patients assessed by PET/CT staging (having stage I to II disease) had no evidence of BMI detected by both PET/CT and BMB. Image-guided biopsy was also recommended when PET/CT showed a focal FDG uptake outside the iliac crest. Survival analysis revealed that BMB was significant for overall survival (OS) (P = 0.020) while M/L for both progression free survival (P = 0.002) and OS (P < 0.001). In multivariate analysis, M/L (HR 1.825, 95% CI 1.071-3.110, P = 0.027) was an independent prognostic factor for OS. There were no statistical differences at the genetic level about BMI confirmed by PET or BMB.

Conclusion: PET/CT has a complementary role in assessing BMI and an ability to predict prognosis in PTCL patients.

查看原文本刊更多论文

治疗前[18F]FDG PET/CT用于评估新诊断的外周T细胞淋巴瘤患者的骨髓受累情况和预后。

目的：探讨[18F]氟脱氧葡萄糖（FDG）-正电子发射断层扫描（PET）/计算机断层扫描（CT）在新诊断的外周T细胞淋巴瘤（PTCL）治疗前评估骨髓受累（BMI）和预后的价值：这项回顾性研究纳入了201例符合条件的PTCL患者，他们在治疗前接受了骨髓活检（BMB）和PET/CT检查。采用目测和定量指标（骨髓的最大标准化摄取值[SUVmax]除以肝脏的SUVmax[M/L]）评估PET检测的骨髓（BM）状态：结果：148 名患者的 PET 或 BMB 均未显示 BMI；16 名患者的两种方法均检测出 BMI。PET/CT 对 BMB 确诊 BMI 患者的敏感性和特异性分别为 43.2% 和 90.2% (κ = 0.353)。此外，25 名通过 PET/CT 分期评估的患者（疾病处于 I 期至 II 期）在 PET/CT 和 BMB 检测中均未发现 BMI 的证据。当 PET/CT 显示髂嵴外有局灶性 FDG 摄取时，也建议在图像引导下进行活检。生存分析显示，BMB对总生存期（OS）有显著影响（P = 0.020），而M/L对无进展生存期（P = 0.002）和OS（P = 0.027）都是OS的独立预后因素。PET或BMB证实的BMI在基因水平上没有统计学差异：结论：PET/CT 在评估 PTCL 患者的 BMI 和预测预后方面具有补充作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology 医学-血液学

CiteScore

2.60

自引率

5.30%

发文量

140

审稿时长

3 months

期刊介绍： Hematology is an international journal publishing original and review articles in the field of general hematology, including oncology, pathology, biology, clinical research and epidemiology. Of the fixed sections, annotations are accepted on any general or scientific field: technical annotations covering current laboratory practice in general hematology, blood transfusion and clinical trials, and current clinical practice reviews the consensus driven areas of care and management.